Business Context and Reporting Period
This Form 8-K Current Report is filed by Aziyo Biologics, Inc. (trading symbol: AZYO) for the reporting period ending November 30, 2022. The registrant is a Delaware corporation focused on product development and clinical research. The filing discloses two material events: the entry into an underwriting agreement for a public equity offering and an amendment to an existing credit agreement.
Key Financial Metrics and Agreements
Equity Offering
- Shares Offered: 2,350,000 shares of Class A common stock.
- Offering Price: $4.75 per share.
- Over-Allotment Option: Underwriter granted an option to purchase up to 352,500 additional shares within 30 days.
- Expected Net Proceeds: Approximately $9.84 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Expansion of product development and clinical research, hiring sales personnel for product launches, and funding working capital/general corporate purposes.
Debt and Credit Facilities
- Amendment Date: November 30, 2022.
- Additional Term Loan: $4 million (Subsequent Term Loan).
- Condition Precedent: Funding is contingent upon the Company issuing additional equity interests resulting in net proceeds of not less than $10 million on or prior to December 16, 2022.
- Waiver: Lenders agreed to fund the loan despite the Company not having satisfied specified operational and financial metrics required for availability.
Material Changes and Unusual Items
The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) as it is a current report regarding specific corporate actions rather than a periodic financial statement. The primary material change is the restructuring of the Company's capital structure through a simultaneous equity raise and debt amendment. Notably, the $4 million term loan funding is conditional on the successful completion of the equity offering, creating a direct linkage between the two transactions.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize the net proceeds to accelerate product development and prepare for commercialization via sales hiring. The closing of the offering is expected on or about December 5, 2022.
Risks and Contingencies:
- Offering Consummation: The equity offering is subject to customary closing conditions; failure to close would impact the ability to satisfy the "Equity Raise Condition" for the $4 million term loan.
- Forward-Looking Statements: The report contains forward-looking statements regarding the anticipated proceeds and use of funds, which are subject to inherent risks and uncertainties. Actual results may differ materially.
- Financial Metrics: The Company has not met the operational and financial metrics typically required for the term loan, relying on the equity raise as a substitute condition.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds of the equity offering against the expected $9.84 million.
- Confirm whether the "Equity Raise Condition" (net proceeds of at least $10 million) was satisfied to trigger the $4 million term loan funding.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Amendment Letter (Exhibit 10.1) for specific covenants and termination provisions.
- Check subsequent filings to determine if the over-allotment option was exercised by the underwriter.
- Assess the Company's cash runway post-offering given the stated intent to fund working capital and clinical activities.